Company intelligence / Profile preview

Huaweite

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Huaweite is a Chinese biopharmaceutical company primarily focused on the development and commercialization of hemostatic products and recombinant protein therapeutics. The company is best known for its flagship product, Recombinant Human Thrombin, which is used to control capillary and small venule bleeding during surgical procedures. Huaweite operates integrated facilities for research, development, and large-scale GMP manufacturing. Its portfolio addresses critical needs in surgical care, emergency medicine, and wound management through advanced biotechnology applications.

Therapeutic areas: HematologyGastroenterology
Modalities: Recombinant proteinSmall moleculeBiologic
Industry: Biotech

Beyond the preview

Go deeper on Huaweite.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huaweite.

Explore the full profile